Tetrazoles as PPARγ ligands: A structural and computational investigation

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Structural Biology

Background:

• Type 2 diabetes affects over 420 million globally, with limited safe pharmacological options.
• Thiazolidinediones (TZDs) for diabetes were withdrawn due to safety concerns, creating a treatment gap.
• Peroxisome Proliferated-Activated Receptor gamma (PPARγ) activation is a key therapeutic target.

Purpose of the Study:

• To screen for novel chemical probes targeting PPARγ using a structure-based approach.
• To investigate the potential of tetrazole compounds for diabetes treatment.
• To elucidate the binding mode of a novel tetrazole compound with PPARγ.

Main Methods:

• Structure-based screening and identification of tetrazole compounds.
• In vitro evaluation of compound binding affinity to PPARγ ligand binding domain (LBD).
• Computational simulations (Monte Carlo) and X-ray crystallography (2.3 Å) of PPARγ-LBD-compound complex.

Main Results:

• Tetrazole compounds T1, T2, and T3 demonstrated micromolar binding affinity for PPARγ-LBD.
• Monte Carlo simulations indicated favorable interactions between the tetrazole ring and the PPARγ binding pocket.
• Crystal structure revealed a T2 binding mode, including an H12-dependent alternative conformation.

Conclusions:

• Tetrazole compounds represent promising chemical probes for PPARγ activation.
• The identified compounds offer potential for developing new type 2 diabetes therapeutics.
• Structural insights provide a basis for further optimization of PPARγ-targeting drugs.